Notice NOT-GM-23-050 from the NIH Guide for Grants and Contracts

Notice NOT-MH-23-365 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AT-24-004 from the NIH Guide for Grants and Contracts. The purpose of this NOFO is to solicit UG3/UH3 phased cooperative agreement research applications to conduct efficient, large-scale pragmatic clinical trial and/or implementation science Demonstration Projects within the infrastructure of the NIH-DoD-VA Pain Management Collaboratory (PMC) on nonpharmacologic approaches to pain management and other comorbid conditions in U.S. veterans, military personnel, and their families. The PMC established a Coordinating Center that provides national leadership and technical expertise for all aspects of health care system (HCS)-focused research including assistance to UG3/UH3 grant awardees.

Funding Opportunity RFA-HL-24-009 from the NIH Guide for Grants and Contracts. This NOFO will support preliminary studies aimed to obtain information necessary to guide the design of a full randomized control trial to test whether sleep and circadian targeted interventions improve the clinical course and treatment outcomes in individuals with Type 1 Diabetes (T1D). Applications should focus on pilot studies to inform practical and potentially sustainable strategies to improve processes of care and cardiometabolic health outcomes in individuals with T1D. The scope of research for this NOFO includes a range of feasibility metrics (e.g., optimizing recruitment, retention, randomization); intervention logistics (e.g., determine independent variable(s), dose-response, duration); study design/statistical considerations (e.g., determination of effect size, sample size, and statistical power; inclusion/exclusion criteria, control variables); adherence outcomes (measures of patient acceptance of, satisfaction with, and adherence to treatment); assessment of intermediate markers of the intervention (e.g. glycemic control, vascular dysfunction, inflammation, and/or neuroendocrine and metabolic function); and selection of primary and/or secondary outcome(s) measures. Ultimately, results from these pilot studies will be used to develop a well-powered, evidence-based definitive clinical trial that could improve clinical care and cardiometabolic outcomes in individuals with T1D and to inform guidelines for this patient population. Transdisciplinary investigative teams including relevant expertise in sleep/circadian, T1D and cardiovascular research, as well as needed expertise in clinical trial design, biostatistics and other appropriate areas are encouraged. Studies should include active participation of children, adolescents, and/or adults with T1D. This program is not intended to develop or validate new treatments of devices for sleep and/or circadian deficiency. Animal studies will not be considered responsive to this initiative.

Funding Opportunity RFA-HL-24-008 from the NIH Guide for Grants and Contracts. The purpose of this NOFO is to elucidate the contribution of sleep deficiency and circadian disruption to metabolic and cardiovascular pathobiology, disease trajectory, and treatment response in individuals living with Type 1 Diabetes (T1D). The RFA will support clinically relevant, mechanism focused research on the interface between sleep, circadian rhythms biology, T1D and cardiovascular disease. Multi-disciplinary teams bridging sleep/circadian, diabetes, and cardiovascular research are encouraged. Proposed research should be relevant to the ultimate goal of applying sleep and circadian strategies to improve treatment and outcomes in individuals with T1D, and to mitigate related cardiovascular complications. Observational studies, epidemiology, efficacy trials and basic animal research will not be responsive to this NOFO.

Notice NOT-HD-23-020 from the NIH Guide for Grants and Contracts

Notice NOT-HD-23-023 from the NIH Guide for Grants and Contracts

Notice NOT-HD-23-022 from the NIH Guide for Grants and Contracts

Notice NOT-AG-23-042 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DA-24-063 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to support research focusing on the identification of druggable new targets and discovery of optimizable probes for development of safe and efficacious medications to prevent and treat opioid use disorders (OUDs), opioid overdose, and opioid-polysubstance use comorbidities. This notice of funding opportunity is part of the NIH Helping to End Addictions Long-term (HEAL) initiative to accelerate the development of novel medications to treat all aspects of the opioid addiction cycle, including progression to chronic use, withdrawal symptoms, craving, relapse, and overdose.

Funding Opportunity RFA-DA-24-064 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to support research focusing on the identification of druggable new targets and discovery of optimizable probes for development of safe and efficacious medications to prevent and treat opioid use disorders (OUDs), opioid overdose, and opioid-polysubstance use comorbidities. This notice of funding opportunity is part of the NIH Helping to End Addictions Long-term (HEAL) initiative to accelerate the development of novel medications to treat all aspects of the opioid addiction cycle, including progression to chronic use, withdrawal symptoms, craving, relapse, and overdose.

Funding Opportunity RFA-AG-24-050 from the NIH Guide for Grants and Contracts. This NOFO invites R61/R33 applications that address health equity, drug costs, and access to new therapeutics or repurposed drugs for Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). Successful applications will seek to identify preferences for pharmacological treatment among racial and ethnic minority people living with AD/ADRD, assess whether cost barriers to pharmacological care exist for racial and ethnic minority people living with AD/ADRD, and quantify expenditures and health- related quality of life (HRQoL) among people interested in receiving novel or repurposed drugs for AD/ADRD. This NOFO will support a study development phase (R61) to conduct rigorous stakeholder engagement with racial and ethnic minority groups to identify, measure, and assess the demand for new and repurposed drugs, and if successful, grantees will transition to an R33 phase for implementation of rigorous modeling of costs and health-related quality of life and dissemination of model findings.

Funding Opportunity RFA-DA-25-014 from the NIH Guide for Grants and Contracts. The goal of this funding opportunity announcement is to generate brain region and cell-type specific microglial protein profiles in the context of HIV and SUD, then use those molecular profiles and interaction networks to establish mechanisms of how HIV-harboring microglia may contribute specifically to neuropathologies encountered with comorbid HIV and SUD.

Funding Opportunity PAR-23-239 from the NIH Guide for Grants and Contracts. This initiative seeks to solicit applications for research projects that address the link between social disconnection including both objective social isolation as well as perceived social isolation (otherwise known as loneliness) and suicide in late-life. Emphasis is placed on research that identifies neurobiological and environmental mechanisms associated with social isolation and loneliness that increase risk for suicidal thoughts and behavior in late-life, that uses an experimental therapeutics approach to identify targets and develop and test interventions to prevent late-life suicide, and that develops new and modifies existing service delivery models to enhance social connection in late-life to prevent suicide.

Funding Opportunity PAR-23-238 from the NIH Guide for Grants and Contracts. This initiative seeks to solicit applications for research projects that address the link between social disconnection including both objective social isolation as well as perceived social isolation (otherwise known as loneliness) and suicide in late-life. Emphasis is placed on research that identifies neurobiological and environmental mechanisms associated with social isolation and loneliness that increase risk for suicidal thoughts and behavior in late-life, that uses an experimental therapeutics approach to identify targets and develop and test interventions to prevent late-life suicide, and that develops new and modifies existing service delivery models to enhance social connection in late-life to prevent suicide.

Notice NOT-MD-23-016 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DA-25-020 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to support the testing of enhanced models of care that optimally integrate HIV, addiction, and primary care services.

Funding Opportunity RFA-DA-25-019 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to support the testing of enhanced models of care that optimally integrate HIV, addiction, and primary care services.

Notice NOT-MH-23-200 from the NIH Guide for Grants and Contracts

Notice NOT-ES-23-014 from the NIH Guide for Grants and Contracts